The present disclosure provides pharmaceutical agents of the formula: ##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

The present disclosure provides pharmaceutical agents of the formula: ##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

The present disclosure provides pharmaceutical agents of the formula:

##STR00001##

wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

The present disclosure provides pharmaceutical agents of the formula:

##STR00001##

wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

An object of the present invention is to provide an industrially advantageous method for producing uracil compound, which is a production intermediate of a 2,6-dioxo-3,6-dihydropyrimidine compound, and ureidomethylene compound applicable as a raw material for uracil compounds. The present invention is characterized in that uracil compound, which is a production intermediate of a 2,6-dioxo-3,6-dihydropyrimidine compound, is produced by subjecting a compound of formula (II) below or a salt thereof to chemical reaction in the presence of an organic base or an inorganic base. In formula (II), X.sup.1 represents a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group, X.sup.2 represents a hydrogen atom or a substituted or unsubstituted linear C1-6 alkyl group, etc., R.sup.1 represents a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group, etc., R.sup.2 represents a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group, and R.sup.3 represents a substituted or unsubstituted C1-6 alkyl group, etc.

##STR00001##

An object of the present invention is to provide an industrially advantageous method for producing uracil compound, which is a production intermediate of a 2,6-dioxo-3,6-dihydropyrimidine compound, and ureidomethylene compound applicable as a raw material for uracil compounds. The present invention is characterized in that uracil compound, which is a production intermediate of a 2,6-dioxo-3,6-dihydropyrimidine compound, is produced by subjecting a compound of formula (II) below or a salt thereof to chemical reaction in the presence of an organic base or an inorganic base. In formula (II), X.sup.1 represents a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group, X.sup.2 represents a hydrogen atom or a substituted or unsubstituted linear C1-6 alkyl group, etc., R.sup.1 represents a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group, etc., R.sup.2 represents a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group, and R.sup.3 represents a substituted or unsubstituted C1-6 alkyl group, etc.

##STR00001##

The present disclosure provides pharmaceutical agents of the formula: ##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

The present disclosure provides pharmaceutical agents of the formula:

##STR00001##

wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

A compound of formula (Ic) ##STR00001## wherein X.sup.2 represents a CONR.sub.k group, wherein R.sub.k represents a hydrogen atom or a methyl group, a NHCONH group, a OCH.sub.2 group, a CH(OH) group, a NHCO group, a O group, a O(CH.sub.2).sub.sO, a CO group, a SO.sub.2 group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, a NHSO.sub.2 or a SO.sub.2NH group; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a ##STR00002##
a ##STR00003##
group, a ##STR00004##
group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, a piperidinyl group, or a CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

A compound of formula (Ic) ##STR00001## wherein X.sup.2 represents a CONR.sub.k group, wherein R.sub.k represents a hydrogen atom or a methyl group, a NHCONH group, a OCH.sub.2 group, a CH(OH) group, a NHCO group, a O group, a O(CH.sub.2).sub.sO, a CO group, a SO.sub.2 group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, a NHSO.sub.2 or a SO.sub.2NH group; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a ##STR00002##
a ##STR00003##
group, a ##STR00004##
group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, a piperidinyl group, or a CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.